BioSpace News Archive

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the quarter ended September 30, 2021, and highlighted recent accomplishments.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2021 and updated financial guidance for 2021.

Aldeyra Therapeutics, Inc., a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences.

Ligand Pharmaceuticals Incorporated announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, and the other featuring Ligand’s existing collection of core royalties and the technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business.

Omeros Corporation announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2021, which include:

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, announced that it has agreed to acquire Eton Bioscience, a privately held provider of synthetic biology products and services.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the third quarter 2021 and changes to its leadership team.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Tom Keuer, Chief Operating Officer, will present at the Q4 Virtual Investor Summit being held November 16-17, 2021.

Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference which will be available for on-demand viewing starting Thursday, November 18 at 3:00 a.m. EST.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, reported recent business progress and third-quarter financial results.